President & CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Make an AppointmentAdult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAfrican American ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingHealthcare ProfessionalsCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Five New Members Elected to Joslin Diabetes Center Board of Trustees

BOSTON (January 14, 2014) – Joslin Diabetes Center today announced that five new members have been elected to its Board of Trustees:

  • Michael Astrue, former Commissioner of Social Security;
  • James Geraghty, Entrepreneur-in-Residence at Third Rock Ventures, LLC;
  • Roberta Herman, MD, former Chief Operating Officer of Harvard Pilgrim Health Care, Inc.;
  • Jessica Hopfield, PhD, former partner, McKinsey & Company; and
  • Barry Libert, Chief Executive Officer of OpenMatters.

“We are pleased to add such a diverse and talented group of individuals to our Board of Trustees,” said John L. Brooks III, President and CEO of Joslin Diabetes Center.  “Their wealth of experience will be invaluable as we pursue our mission at Joslin of providing the best possible diabetes care and education while undertaking research aimed at finding a cure. In addition, their unique perspectives will assist us as we harness the power of technology, connectivity, mobility, and big data to bring real actionable information and insights to patients, their families, and care teams, while eliminating much of the day-to-day burden of managing diabetes.”

As Commissioner of Social Security from 2007 to 2013, Michael Astrue oversaw the Social Security Administration, an independent federal agency with over 62,000 employees nationwide.  Prior to his appointment as Commissioner, he worked for 14 years in the Massachusetts biotechnology industry, most notably as General Counsel of Biogen and as the CEO brought in to lead the highly successful turnaround of Transkaryotic Therapies (TKT).  He previously served as Associate Counsel to Presidents Reagan and Bush and as General Counsel of the U.S. Department of Health and Human Services.  Mr. Astrue is an honors graduate of Yale University and Harvard Law School.

James Geraghty joined Third Rock Ventures, a venture capital firm focused on building healthcare companies, in 2013.  Prior to joining Third Rock, he served as Senior Vice President, North America Strategy and Business Development at Sanofi, where he spearheaded the company’s strategy for international diabetes care.  He previously spent 20 years at Genzyme Corporation, most recently as Senior Vice President and an Officer.  A graduate of Yale Law School, Mr. Geraghty holds an MS from the University of Pennsylvania and a BA from Georgetown University.

Roberta Herman, M.D. served as Chief Operating Officer of Harvard Pilgrim Health Care from 2010 to 2013, with responsibility for the day-to-day operations of one of New England’s largest non-profit managed health care organizations.  Before becoming COO, Dr. Herman served as Chief Medical Officer where she oversaw Harvard Pilgrim's clinical departments, including health promotion, disease management, pharmacy services, behavioral health, and quality and utilization programs.  Dr. Herman graduated from McGill University Medical School and received a Masters equivalent degree in Epidemiology and Biostatistics from McGill University.

As a partner in McKinsey & Company’s Global pharmaceutical Practice from 1995 to 2009, Jessica Hopfield, Ph.D. served clients across the pharmaceutical, biotech, medical device and consumer industries with a focus on strategy formulation, R&D management and marketing.  In 2010 she founded J Hopfield Consulting to provide strategic guidance and executive coaching to start-up technology firms seeking to commercialize intellectual property.  Ms. Hopfield earned a BS from Yale College, an MBA from Harvard Graduate School of Business Administration and a PhD in neuroscience/biochemistry from the Rockefeller University.

Barry Libert has spent the last decade founding, investing in, and advising social software and analytics companies, including Mzinga, Innocentive, The Pulse Network, MedNetworks, and many more. Together, these firms manage more than 15,000 online communities with nearly 50 million users for more than 350 public and private organizations. The author of five books and 14 e-books on social and open business models, transparency and authentic leadership, and governance, he previously held positions with McKinsey & Company, Arthur Andersen, and the John Hancock.  Mr. Libert received his BA from Tufts University and his MBA from Columbia University.

###